Table 4.

Associations of urinary arsenic metabolites, MTHFR, and GSTO1 genotypes/diplotypes with risk of skin lesions

n*
ORs for skin lesions (95% CI)ORs for skin lesions (95% CI)P for trend
CasesControls
%InAs
    0-11.1 (8.4)1532551.01.00.99
    11.2-14.7 (12.9)1492601.02 (0.74-1.42)1.00 (0.71-1.40)
    14.8-18.7 (16.7)1402690.91 (0.66-1.26)0.79 (0.56-1.11)
    18.9-69.3 (24.6)1522571.27 (0.92-1.76)1.02 (0.72-1.45)
PMI, MMA/InAs
    0-0.63 (0.46)923151.01.00.11
    0.64-0.90 (0.77)1532561.52 (1.08-2.14)1.43 (1.00-2.04)
    0.91-1.22 (1.05)1592481.32 (0.94-1.86)1.35 (0.95-1.93)
    0.23-19.57 (1.75)1892191.44 (1.02-2.03)1.38 (0.96-1.98)
%MMA
    0-9.7 (7.5)893201.01.00.01
    9.8-12.8 (11.4)1322761.30 (0.92-1.85)1.33 (0.92-1.93)
    12.9-16.4 (14.5)1702401.74 (1.23-2.46)1.68 (1.17-2.42)
    16.5-33.7 (20.2)2032051.91 (0.35-2.70)1.57 (1.10-2.26)
%DMA
    27.9-65.0 (58.6)1812271.01.00.09
    65.1-70.8 (68.1)1632470.80 (0.59-1.09)0.93 (0.67-1.29)
    70.9-76.0 (73.3)1292790.63 (0.46-0.87)0.80 (0.57-1.12)
    76.1-100.0 (80.3)1212880.64 (0.46-0.89)0.83 (0.58-1.18)
SMI (DMA/MMA)
    1.5-3.9 (3.1)2052021.01.00.01
    4.0-5.5 (4.7)1602470.77 (0.56-1.04)0.88 (0.64-1.21)
    5.6-7.6 (6.4)1342730.63 (0.46-0.86)0.78 (0.56-1.09)
    7.7-32.3 (10.9)943130.52 (0.37-0.73)0.64 (0.44-0.91)
MTHFR 677 (rs1801133)
    CC4167391.001.000.23
    CT1241851.14 (0.86-1.53)1.14 (0.84-1.54)
    TT12111.55 (0.60-3.99)1.56 (0.57-4.30)
MTHFR 1298 (rs1801131)
    CC631351.001.000.09
    CA2504361.07 (0.73-1.56)1.11 (0.75-1.66)
    AA2343361.36 (0.93-2.01)1.37 (0.91-2.06)
MTHFR diplotypes
    Other/other2243251.001.000.06
    CC/other2464320.77 (0.59-1.00)0.80 (0.61-1.05)
    CC/CC611310.73 (0.49-1.08)0.72 (0.48-1.09)
    Other/other1222231.001.000.35
    CA/other2684481.12 (0.83-1.51)1.19 (0.87-1.63)
    CA/CA1412171.21 (0.86-1.71)1.19 (0.83-1.72)
    Other/other3996991.001.000.22
    TA/other1201781.16 (0.87-1.56)1.17 (0.86-1.59)
    TA/TA12111.54 (0.60-3.98)1.55 (0.57-4.27)
MTHFR diplotypes
    CC CC611311.001.000.12
    CC CA1973511.06 (0.72-1.58)1.13 (0.75-1.71)
    CA CA1412171.26 (0.83-1.92)1.25 (0.80-1.94)
    CC TA49811.01 (0.60-1.70)1.01 (0.58-1.74)
    CA TA71971.58 (0.97-2.57)1.66 (1.00-2.77)
    TA TA12111.72 (0.63-4.67)1.77 (0.61-5.14)
GSTO1 (rs4925)
    CC3776331.001.000.39
    CA1492701.00 (0.77-1.31)0.98 (0.74-1.29)
    AA24301.65 (0.88-3.07)1.73 (0.91-3.30)
GSTO1 (rs11509437)
    AA4537131.001.000.11
    AT821550.83 (0.60-1.14)0.85 (0.60-1.19)
    TT4160.30 (0.09-0.95)0.45 (0.14-1.44)
GSTO1 (rs11509438)
    GG4507221.001.000.22
    GA841650.87 (0.63-1.20)0.88 (0.63-1.24)
    AA5160.36 (0.12-1.05)0.52 (0.18-1.52)
GSTO1 diplotypes
    Other/other4246741.001.000.27
    CTA/other771400.92 (0.65-1.28)0.92 (0.65-1.32)
    CTA/CTA4160.30 (0.10-0.97)0.45 (0.14-1.44)
    Other/other3455681.001.000.24
    AAG/other1382341.03 (0.78-1.36)1.02 (0.76-1.37)
    AAG/AAG22281.67 (0.88-3.19)1.84 (0.94-3.60)
    Other/other41661.001.000.80
    CAG/other1853300.89 (0.55-1.44)0.84 (0.51-1.38)
    CAG/CAG2794340.95 (0.60-1.52)0.87 (0.54-1.41)
GSTO1 diplotypes
    CTA CTA4161.001.000.15
    CTA AAG15223.69 (0.95-14.39)2.24 (0.55-9.10)
    CAG CTA621182.89 (0.87-9.56)2.03 (0.61-6.83)
    CAG CAG2794343.26 (1.02-10.40)2.19 (0.68-7.06)
    CAG AAG1232123.14 (0.97-10.17)2.15 (0.66-7.07)
    AAG AAG22285.21 (1.41-19.28)3.91 (1.03-14.79)
  • * Data were missing on PMI for cases and controls, respectively, 1 and 3 subjects; on SMI for 1 and 6 subjects; on MTHFR 677 (rs1801133) for 42 and 106 subjects; on MTHFR 1298 (rs1801131) for 47 and 134 subjects; on MTHFR 677 (rs1801133) for 42 and 106 subjects; on MTHFR diplotypes for 62 and 153 subjects; on GSTO1 (rs4925) for 44 and 108 subjects; on GSTO1 (rs11509438) for 55 and 138 subjects; on GSTO1 (rs11509437) for 55 and 157 subjects, and on GSTO1 diplotypes for 88 and 210 subjects.

  • ORs were adjusted for sex and age.

  • ORs were adjusted for sex, age, BMI, smoking status, well arsenic concentration, and water consumption per day. Subjects with missing on BMI were additionally excluded from the analysis.